Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 9/20 | 0.37 |
| ▸ | TRPM4 | Q8TD43 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27663129 | 0.88 | CHEK1 (0.42) | TRPM5TRPM4GAAALPLCA2 | |
| SCHEMBL20804518 | 0.84 | AR (0.40) | GAAMAP3K14ALPLRIPK1CA2 | |
| SCHEMBL17363934 | 0.82 | NR3C1 (0.42) | RIPK1 | |
| SCHEMBL17363948 | 0.82 | NR3C1 (0.42) | RIPK1 | |
| SCHEMBL17363890 | 0.82 | NR3C1 (0.42) | RIPK1 | |
| SCHEMBL24776144 | 0.81 | GAA (0.37) | GAAALPLCA2 | |
| SCHEMBL3587070 | 0.81 | GAA (0.37) | GAA | |
| SCHEMBL13544000 | 0.81 | GAA (0.37) | GAA | |
| SCHEMBL3587072 | 0.81 | GAA (0.37) | GAA | |
| SCHEMBL3591700 | 0.81 | GAA (0.37) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | disclosed |
| WO-2008052075-A2 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HTR2C, HTR5A, NPY1R | TRPM5 695/4885TRPM4 847/4885GAA 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.